Novo Nordisk's Stock Dips In Pre-Market Despite Winning UK's Approval Of Weight Loss Drug: What's Going On
Novo Nordisk's Stock Dips In Pre-Market Despite Winning UK's Approval Of Weight Loss Drug: What's Going On
In Wednesday's pre-market trading, shares of Novo Nordisk A/S (NYSE:NVO) are witnessing a fall after the U.K.'s Medicines and Healthcare products Regulatory Agency (MHRA) approved a new indication for Novo Nordisk's semaglutide, Wegovy, to reduce the risk of heart complications or strokes in overweight and obese adults,
週三盤前交易中，Novo Nordisk A/S (NYSE:NVO) 的股票價格下跌，此前英國藥品與保健品管制局 (MHRA) 批准了 Novo Nordisk 的一種新型治療藥Semaglutide（商標名爲Wegovy），旨在減少超重和肥胖成年人心臟併發症或中風的風險。
What Happened: At the time of writing, Novo Nordisk was trading 1.25% lower at $131.61 in the pre-market after closing at $133.28 on Tuesday, according to Benzinga Pro.
事件經過：截至撰寫本文時，Novo Nordisk 的股票交易價格爲131.61美元，較週二的133.28美元下跌1.25%，據Benzinga Pro報道。
The weak pre-market performance can also be linked to increased competition in the weight loss drugs market. Last week, shares of Novo Nordisk and rival Eli Lilly (NYSE:LLY) dipped after Pfizer Inc. (NYSE:PFE) and Roche (OTC:RHHBY) announced their advancements in obesity-fighting drugs.
對於 Novo Nordisk 股票的弱勢盤前表現，也可以歸因於減重藥市場競爭加劇。上週，Novo Nordisk 和競爭對手 Eli Lilly (NYSE:LLY) 的股票價格都出現下跌，此前輝瑞（Pfizer Inc.，NYSE:PFE）和羅氏（Roche，OTC:RHHBY）宣佈其在治療肥胖方面的藥物研發取得了進展。
Wegovy, a GLP-1 receptor agonist, had previously been approved for use in obesity treatment and weight management, in combination with diet, physical activity, and behavioral support.
Semaglutide是一種GLP-1受體激動劑，先前已經獲得批准用於肥胖治療和體重管理，可以和飲食、體育鍛煉和行爲支持相結合使用。
This latest approval marks semaglutide as the first weight loss drug to be prescribed for the prevention of cardiovascular events, such as cardiovascular death, non-fatal heart attack, and non-fatal stroke, in individuals with established cardiovascular disease and a Body Mass Index (BMI) of 27 kg/m2 or higher.
這種最新的藥品批准標誌着Semaglutide成爲可用於預防心血管事件的第一種減肥藥物，例如心血管死亡、非致命性心肌梗塞和非致命性中風，適用於已經患有心血管疾病和身體質量指數（BMI）爲27 kg/m2或更高的個人。
The approval is based on new data from a post-approval clinical study, which demonstrated that semaglutide (2.4 mg once weekly by subcutaneous injection for up to five years) reduces the occurrence of major adverse cardiovascular events (MACE) compared to a placebo.
該批准基於一項最新的批准後臨床研究數據，顯示皮下注射1周2.4毫克的Semaglutide（最長爲5年）與安慰劑相比，可以減少重大不良心血管事件（MACE）的發生。
Why It Matters: This approval comes after Novo Nordisk acquired Cardior Pharmaceuticals GmbH in April, a biotech company focusing on heart diseases, as the Danish pharma giant sought to build its heart drugs pipeline.
此次批准是在Novo Nordisk於4月份收購了心臟疾病生物技術公司Cardior Pharmaceuticals GmbH之後才獲得的，作爲丹麥製藥巨頭增強其心血管藥品管道。
In June, Wegovy demonstrated greater weight loss in women with prevalent heart disease than in men with the same condition. The drug led to similar improvements in heart failure symptoms in both genders, but women lost an average of 9.6% of their weight, compared to men who lost about 7.2% of body weight.
今年6月，Wegovy對於患有普遍心臟病的女性而言的減重效果優於男性。該藥物對於兩性的心力衰竭症狀改善類似，但女性平均減重9.6%，而男性只減少了7.2%的體重。
- Craze For Ozempic And Zepbound For Weight Loss Leave Diabetic Patients Without Critical GLP-1 Medications
- Ozempic和Zepbound的減肥效應熱潮讓糖尿病患者沒了重要的GLP-1類藥物
Photo by Tobias Arhelger via Shutterstock
圖片由shutterstock提供
This story was generated using Benzinga Neuro and edited by Pooja Rajkumari
本報道使用Benzinga Neuro生成，並由Pooja Rajkumari編輯